Heat shock protein 105 kDa (HSP110) complexed with Melanocyte protein PMEL (gp100) (HSP110-gp100)

The Human HSP110-gp100 complex is a therapeutic target and vaccine construct primarily investigated for the treatment of melanoma. HSP110 (also known as HSPH1 or Heat shock protein 105 kDa) is a member of the heat shock protein 70 superfamily that functions as a molecular chaperone, while gp100 (Melanocyte protein PMEL) is a melanocyte-specific protein frequently overexpressed in melanoma cells (UniProt: P11021, P40967). In this interaction, HSP110 acts as a powerful protein-based adjuvant that binds to gp100, stabilizing the antigen and promoting its uptake by professional antigen-presenting cells, such as dendritic cells, through receptor-mediated endocytosis (Wang et al., 2001). This process facilitates the cross-presentation of gp100-derived peptides on MHC class I molecules, leading to the robust activation of tumor-specific CD8+ cytotoxic T lymphocytes (Manjili et al., 2002). Research has demonstrated that HSP110-gp100 complexes are significantly more effective at eliciting anti-tumor immune responses than gp100 alone in preclinical models, effectively overcoming immune tolerance to self-antigens. Clinical and preclinical studies focus on using this complex to induce long-lasting protective immunity and reduce tumor burden in patients with advanced melanoma. The interaction is specifically engineered to enhance the immunogenicity of tumor-associated antigens that are otherwise poorly recognized by the immune system.

Other names

HSPH1-PMEL complexHSP110-PMEL17gp100-HSP110 vaccineHeat shock protein 110-gp100 complexHSP105-gp100Chaperone-gp100 complex

The complex acts as an immunotherapeutic agent where HSP110 serves as a chaperone-adjuvant to deliver the gp100 antigen to dendritic cells, promoting receptor-mediated endocytosis, cross-presentation, and the generation of a robust cytotoxic T-lymphocyte response against melanoma cells (Wang et al., 2001; PubMed: 11418638).